Investigating how psychedelics affect brain plasticity using a small worm model.
Genetic analysis of psychoplasticity in C. elegans
['FUNDING_R21'] · UNIVERSITY OF OREGON · NIH-11048602
This study is looking at how psychedelics might help the brain grow new connections, which could be beneficial for people dealing with depression and PTSD.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF OREGON (nih funded) |
| Locations | 1 site (EUGENE, UNITED STATES) |
| Trial ID | NIH-11048602 on ClinicalTrials.gov |
What this research studies
This research explores the effects of psychedelics on brain plasticity, particularly in relation to psychiatric conditions like depression and PTSD. By using the model organism C. elegans, which shares genetic similarities with humans, the study aims to understand how these substances can promote the growth of new neural connections. The approach focuses on the polypharmacological properties of psychedelics, meaning it looks at how these drugs interact with multiple molecular targets rather than just one. This could lead to more effective treatments for mental health disorders by enhancing our understanding of how psychedelics can reverse neuronal atrophy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from treatment-resistant depression, PTSD, or substance use disorders.
Not a fit: Patients with non-psychiatric conditions or those who do not respond to psychedelic treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved therapeutic strategies for treating severe psychiatric disorders.
How similar studies have performed: Previous studies have shown promising results in using psychedelics for treating psychiatric disorders, indicating that this approach has potential for success.
Where this research is happening
EUGENE, UNITED STATES
- UNIVERSITY OF OREGON — EUGENE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LOCKERY, SHAWN R — UNIVERSITY OF OREGON
- Study coordinator: LOCKERY, SHAWN R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: addictive disorder